An expert discusses what has been learned about the use of bone-protecting agents and bone density scans for patients ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Androgen receptor non-canonical domain binding degrader for treatment of relapsed, refractory castration-resistant prostate cancer: K. Sadasivan Pillai Wednesday, March 5, 2025, 0 ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) ligase binding moiety covalently linked to an ...

Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate ...

Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...

Zydus Lifesciences Ltd. has received final nod from the United States Food and Drug Administration to manufacture 60 mg Apalutamide tablets, according to an exchange filing on Tuesday.

Writing in Cell, Yang et al. identify the adhesion G-protein coupled receptor (aGPCR) GPR133 (also known as ADGRD1) as an androgen membrane receptor for 5α-dihydrotestosterone (5α-DHT ...

Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate ...

Patients with mCRPC prostate cancer have an elevated risk of fractures due to bone metastases and use of androgen receptor pathway inhibitors (ARPI).

As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.